Cantor Fitzgerald analyst Craig Bijou reiterated a Buy rating on AxoGen (AXGN) yesterday and set a price target of $30. The company’s shares closed yesterday at $23.02.
Bijou said:
“: We reiterate our Overweight rating and raise our PT to $30 from $26 on AXGN. We think 1Q growth was a strong start to the year and a big first step to restore investor confidence. AXGN reported 1Q revenue of $23.3MM (+35%), beating FactSet consensus by $1MM. AXGN reiterated its 2019 guidance, but we think that management is being cautious and wants to ensure that there is no lingering disruption from the leadership changes made early in the year. AXGN shares have rebounded considerably since early January, as it moved past many of its issues from 2018.”
According to TipRanks.com, Bijou is a 3-star analyst with an average return of 4.0% and a 47.1% success rate. Bijou covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Ra Medical Systems Inc, and Integra Lifesciences.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for AxoGen with a $31 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $56.85 and a one-year low of $14.13. Currently, AxoGen has an average volume of 512.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provide products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity.
